Latest News & Updates from the HEALEY ALS Platform Trial
Jul 15, 2024 · The ALS Association announced a $3 million commitment to the first platform trial for ALS, taking place at the Sean M. Healey & AMG Center for ALS at Mass General in collaboration with the Barrow Neurological Institute and the Northeast ALS Consortium (NEALS).
Sean M. Healey & AMG Center Announces Update in ALS Platform Trial …
BOSTON – The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital today announced topline results from Regimen F of the HEALEY ALS Platform Trial evaluating f osigotifator (ABBV-CLS-7262) in people living with amyotrophic lateral sclerosis (ALS). Fosigotifator, an eIF2B activator, is an investigational drug being developed by Calico Life Sciences LLC (Calico) in ...
Sean M. Healey & AMG Center Announces Topline Results in HEALEY ALS …
For updates on the trial, please join our HEALEY ALS Platform Trial webinars. The HEALEY ALS Platform Trial is a patient-centric clinical trial designed in collaboration with the Northeast ALS Consortium (NEALS) to accelerate the development of breakthrough treatments for persons with ALS by testing multiple drugs (regimens) at the same time ...
DNL343, fosigotifator fail HEALEY platform trial’s main goal in ALS
19 hours ago · Testing DNL343, fosigotifator in HEALEY trial. The main goal of all the arms is to evaluate a treatment’s ability to slow ALS progression and prolong survival, as assessed by the ALS Functional Rating Scale-Revised (ALSFRS-R), after six months. New arms will be assessed for 36 weeks, or about nine months, following a recent amendment.
Calico Provides Update on Fosigotifator in HEALEY ALS Platform Trial
4 days ago · The HEALEY ALS Platform Trial is a patient-centric clinical trial designed in collaboration with the Northeast ALS Consortium (NEALS) to accelerate the development of breakthrough treatments for persons with ALS by testing multiple drugs (regimens) at the same time with efficient use of patient, scientific, and operational resources. So far ...
Fosigotifator Fails to Meet End Points in HEALEY-ALS Platform Trial
3 days ago · Topline data from regimen F of the HEALEY-ALS Platform trial revealed that fosigotifator (Calico Life Sciences), an investigational eIF2B activator, did not meet its primary end point of slowing disease progression in patients with amyotrophic lateral sclerosis (ALS). ... Sean M. Healey & AMG Center Announces Update in ALS Platform Trial with ...
HEALEY ALS trial to allow longer follow-up, blood cell collection
Dec 20, 2024 · The HEALEY ALS platform trial, which is simultaneously testing multiple potential treatments for amyotrophic lateral sclerosis (ALS), is amending its master protocol to allow a longer follow-up time and collection of blood cells for use in future research.
Patient enrollment complete in DNL343 arm of HEALEY ALS trial
May 14, 2024 · The HEALEY platform trial (NCT04297683), led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), in Boston, is the first study to ever simultaneously test multiple experimental therapies for the neurodegenerative disease.
Denali Therapeutics Announces Topline Results for Regimen G …
3 days ago · Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial Denali Therapeutics Inc. Mon, Jan 6, 2025, 4:30 PM 7 min read
Denali Therapeutics announces HEALEY ALS trial regimen misses …
3 days ago · Denali Therapeutics announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral ...
- Some results have been removed